Febuxostat dose requirement according to renal function in patients who achieve target serum urate levels: A retrospective cohort study

Abstract

ObjectivesTo determine the febuxostat dose requirement according to renal function in patients who achieve target serum urate (SU) levels. MethodsOf 3153 gout patients who underwent febuxostat treatment, 873 patients with an initial SU level>6mg/dL were included and categorized by the estimated glomerular filtration rate: normal, chronic kidney disease (CKD) stage 3, and stages 4–5. Ninety-five patients with insufficient follow-up were further excluded. The dose of febuxostat in patients who achieved the SU target (< 6mg/dL) was defined as the average daily dosage at the time of SU target achievement. ResultsThe cohort of 778 gout patients had a median age of 52.0 years (IQR, 41.0–63.0) and comprised 711 (91.4%) men. The mean SU at febuxostat initiation was higher in the CKD 4–5 (9.6 [± 3.1] mg/dL) than in the other groups (CKD 3, 8.7 [± 1.7]; normal, 8.4 [± 1.7]; P<0.001). Patients achieved target SU at a median of 4.0 (1.9–9.6) months and in those who achieved target SU, the dose of febuxostat at the time of SU target achievement was significantly lower in the CKD 4–5 group (50.0 [± 16.5] mg) than in the other groups (vs. CKD stage 3, 60.0 [± 19.5] mg; P<0.01, vs. normal, 60.0 [± 19.8] mg; P<0.01). Furthermore, CKD stage 4–5 had a negative correlation with the febuxostat dose requirement (Beta: –2.334, P<0.05). ConclusionAmong patients who achieved SU target, those with severely decreased renal function (CKD 4–5) required a lower febuxostat dose to achieve the target SU level compared to patients with normal or mild renal impairment.